J&J Forges Ahead In Immunology Despite Competitive Dynamics

The diversified pharma has two NMEs and three sNDAs pending at FDA in immunology, as well as six more anticipated sNDA filings. Immunology Therapeutic Head Susan Dillon told investors why there is still plenty of opportunity for growth in key autoimmune diseases.

Johnson & Johnson has big expectations for immunology to contribute to the pharmaceutical division's overall growth from 2017 to 2021, powered by two new launches and line extensions for the marketed drugs Stelara (ustekinumab) and Simponi (golimumab).

Despite the increasingly competitive market dynamics in autoimmune diseases like rheumatoid arthritis, Crohn's disease and plaque psoriasis and biosimilar competition...